MedTrace Logo

Prospective Thinking in Hormone-Responsive Breast Cancer

NCT03594578 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2019-10-01

No results posted yet for this study

Summary

One factor that limits the effectiveness of adjuvant hormone therapy for breast cancer is medication nonadherence. Adherence to long-term medication regimens requires valuation of temporally distant outcomes. Thus, interventions that improve valuation of the future, a phenomenon known as delay discounting, may improve medication adherence in breast cancer treatment and improve survival. This study will investigate the acute efficacy of a prospective thinking intervention (episodic future thinking) for reducing delay discounting and improving valuation of future health in breast cancer patients. Patients will engage in either episodic future thinking or a control condition during completion of delay discounting tasks in which they choose between immediate and delayed outcomes.

Conditions

  • Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions

BEHAVIORAL

Episodic future thinking

Prospective thinking intervention

BEHAVIORAL

Episodic recent thinking

Sham episodic thinking

Sponsors & Collaborators

  • Carilion Clinic

    collaborator OTHER

  • Virginia Polytechnic Institute and State University

    lead OTHER

Principal Investigators

  • Jeff S Stein, PhD · Virginia Tech Carilion School of Medicine and Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-09-20
Completion
2019-09-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03594578 on ClinicalTrials.gov